Literature DB >> 18995189

Automated (11)C-PiB standardized uptake value ratio.

Parnesh Raniga1, Pierrick Bourgeat, Jurgen Fripp, Oscar Acosta, Victor L Villemagne, Christopher Rowe, Colin L Masters, Gareth Jones, Graeme O'Keefe, Olivier Salvado, Sébastien Ourselin.   

Abstract

RATIONALE AND
OBJECTIVES: Radiotracers such as (11)C-PiB have enabled the in vivo imaging of amyloid-beta plaques in the brain, one of the histopathologic hallmarks of Alzheimer's disease (AD). Standardized uptake value ratio (SUVR) has become the most common normalization for (11)C-PiB as it does not require dynamic scans or blood sampling. Normalization is performed by computing the ratio of (11)C-PiB retention in the whole brain to that in cerebellar gray matter. However, SUVR is still conducted manually and is time consuming. An automated normalization algorithm is proposed.
MATERIALS AND METHODS: Sixty participants from the Australian Imaging Biomarkers and Lifestyle (AIBL) study were used to test the developed algorithm and compare it against manual SUVR. The cohort consisted of participants likely to have AD (n = 20), those with mild cognitive impairment (MCI; n = 20), and normal controls (NC; n = 20). The participants underwent (11)C-PiB PET scans. A subset (n = 15) also underwent magnetic resonance imaging scans. (11)C-PET scans were segmented using an expectation maximization approach with inhomogeneity correction using three-dimensional cubic B-Splines. A cerebellar region was propagated and constrained by segmentation. Comparisons were made between manual and automated SUVR using regional analysis. Receiver-operating characteristic curves were computed for the task of AD-NC classification. Positron emission tomographic segmentations were also compared to co-registered magnetic resonance images of the same patient.
RESULTS: Significant differences in regional means were observed between manual and automated SUVR. However, these changes were highly correlated (r > 0.8 for most regions). Significant differences (P < .05) in regional variances were also observed for the AD and NC subgroups. Area under the curve was 0.84 and 0.89 for manual and automated SUVR, respectively.
CONCLUSIONS: The automated normalization technique results in less within-group variance and better discrimination between AD and NC participants.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18995189     DOI: 10.1016/j.acra.2008.07.006

Source DB:  PubMed          Journal:  Acad Radiol        ISSN: 1076-6332            Impact factor:   3.173


  10 in total

1.  Evaluation of [11C]TAZA for amyloid β plaque imaging in postmortem human Alzheimer's disease brain region and whole body distribution in rodent PET/CT.

Authors:  Min-Liang Pan; Meenakshi T Mukherjee; Himika H Patel; Bhavin Patel; Cristian C Constantinescu; M Reza Mirbolooki; Christopher Liang; Jogeshwar Mukherjee
Journal:  Synapse       Date:  2016-02-11       Impact factor: 2.562

Review 2.  Amyloid imaging with PET: methodological issues and correlative studies.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-06       Impact factor: 9.236

3.  Perfusion-like template and standardized normalization-based brain image analysis using 18F-florbetapir (AV-45/Amyvid) PET.

Authors:  Ing-Tsung Hsiao; Chin-Chang Huang; Chia-Ju Hsieh; Shiaw-Pyng Wey; Mei-Ping Kung; Tzu-Chen Yen; Kun-Ju Lin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-15       Impact factor: 9.236

Review 4.  PET amyloid-beta imaging in preclinical Alzheimer's disease.

Authors:  Andrei G Vlassenko; Tammie L S Benzinger; John C Morris
Journal:  Biochim Biophys Acta       Date:  2011-11-12

5.  Deep residual inception encoder-decoder network for amyloid PET harmonization.

Authors:  Jay Shah; Fei Gao; Baoxin Li; Valentina Ghisays; Ji Luo; Yinghua Chen; Wendy Lee; Yuxiang Zhou; Tammie L S Benzinger; Eric M Reiman; Kewei Chen; Yi Su; Teresa Wu
Journal:  Alzheimers Dement       Date:  2022-02-09       Impact factor: 16.655

6.  Quantitative Amyloid Imaging in Autosomal Dominant Alzheimer's Disease: Results from the DIAN Study Group.

Authors:  Yi Su; Tyler M Blazey; Christopher J Owen; Jon J Christensen; Karl Friedrichsen; Nelly Joseph-Mathurin; Qing Wang; Russ C Hornbeck; Beau M Ances; Abraham Z Snyder; Lisa A Cash; Robert A Koeppe; William E Klunk; Douglas Galasko; Adam M Brickman; Eric McDade; John M Ringman; Paul M Thompson; Andrew J Saykin; Bernardino Ghetti; Reisa A Sperling; Keith A Johnson; Stephen P Salloway; Peter R Schofield; Colin L Masters; Victor L Villemagne; Nick C Fox; Stefan Förster; Kewei Chen; Eric M Reiman; Chengjie Xiong; Daniel S Marcus; Michael W Weiner; John C Morris; Randall J Bateman; Tammie L S Benzinger
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

7.  Multi-Kernel Learning with Dartel Improves Combined MRI-PET Classification of Alzheimer's Disease in AIBL Data: Group and Individual Analyses.

Authors:  Vahab Youssofzadeh; Bernadette McGuinness; Liam P Maguire; KongFatt Wong-Lin
Journal:  Front Hum Neurosci       Date:  2017-07-25       Impact factor: 3.169

8.  [11C]SCH23390 binding to the D1-dopamine receptor in the human brain-a comparison of manual and automated methods for image analysis.

Authors:  Per Stenkrona; Granville J Matheson; Simon Cervenka; Pontus Plavén Sigray; Christer Halldin; Lars Farde
Journal:  EJNMMI Res       Date:  2018-08-02       Impact factor: 3.138

9.  Quantitative analysis of PiB-PET with FreeSurfer ROIs.

Authors:  Yi Su; Gina M D'Angelo; Andrei G Vlassenko; Gongfu Zhou; Abraham Z Snyder; Daniel S Marcus; Tyler M Blazey; Jon J Christensen; Shivangi Vora; John C Morris; Mark A Mintun; Tammie L S Benzinger
Journal:  PLoS One       Date:  2013-11-06       Impact factor: 3.240

Review 10.  Diagnostic accuracy of (18)F amyloid PET tracers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis.

Authors:  Elizabeth Morris; Anastasia Chalkidou; Alexander Hammers; Janet Peacock; Jennifer Summers; Stephen Keevil
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-11-28       Impact factor: 9.236

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.